What is Viking Therapeutics's operating lease liabilities?

Viking Therapeutics (VKTX) reported operating lease liabilities of -$139K in Q1 2026.

How has Viking Therapeutics's operating lease liabilities changed year-over-year?

Viking Therapeutics's operating lease liabilities decreased by 7.8% year-over-year, from -$129K to -$139K.

What is the long-term trend for Viking Therapeutics's operating lease liabilities?

Over 4 years (2021 to 2025), Viking Therapeutics's operating lease liabilities has grown at a 10.2% compound annual growth rate (CAGR), from -$342K to -$505K.

Viking Therapeutics VKTX Operating lease liabilities

Operating lease liabilities at other companies

Crinetics PharmaceuticalsCRNX

——

Beam TherapeuticsBEAM

——

Edgewise Therapeutics, Inc.EWTX

——

Apogee Therapeutics, Inc.APGE

——

Protagonist TherapeuticsPTGX

——

Mirum Pharmaceuticals, Inc.MIRM

——

Other financials

Income statement

See full

Revenue-—

Operating income-$164.1M-196%

Net income-$158.3M-247%

EPS (diluted)-$1.37-234%

Balance sheet

See full

Cash & equivalents$118.1M+211%

Total debt$137.0K-87.8%

Total equity$501.9M-40.7%

Total assets$608.2M-29.8%

Cash flow

See full

Operating cash flow-$114.0M-118%

Valuation

See full

Market cap$3.53B+38.7%

Returns & leverage

See full

Return on equity-70%-94.5pp

Debt / equity0×0.0×

Current ratio5.7×-38.5×

Where this comes from

Reported directly by Viking Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viking Therapeutics's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Viking Therapeutics's operating lease liabilities?: Viking Therapeutics (VKTX) reported operating lease liabilities of -$139K in Q1 2026.
How has Viking Therapeutics's operating lease liabilities changed year-over-year?: Viking Therapeutics's operating lease liabilities decreased by 7.8% year-over-year, from -$129K to -$139K.
What is the long-term trend for Viking Therapeutics's operating lease liabilities?: Over 4 years (2021 to 2025), Viking Therapeutics's operating lease liabilities has grown at a 10.2% compound annual growth rate (CAGR), from -$342K to -$505K.